These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 20018374)

  • 1. Modifications of fasting glucose values as first sign of resistance in chronic myeloid leukemia chronic phase patients during imatinib treatment.
    Breccia M; Muscaritoli M; Cannella L; Loglisci G; Santopietro M; Alimena G
    Leuk Res; 2010 May; 34(5):e122-4. PubMed ID: 20018374
    [No Abstract]   [Full Text] [Related]  

  • 2. [Circumventing resistance to imatinib therapy in chronic myeloid leukemia].
    Minami Y; Naoe T
    Gan To Kagaku Ryoho; 2009 Apr; 36(4):544-7. PubMed ID: 19381024
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Mechanism and overcome against drug resistance to imatinib for treatment of chronic myeloid leukemia].
    Tauchi T; Oyashiki K
    Gan To Kagaku Ryoho; 2011 May; 38(5):749-53. PubMed ID: 21702118
    [No Abstract]   [Full Text] [Related]  

  • 4. Double Philadelphia-chromosome: a resistance factor on the imatinib mesylate therapy for chronic myeloid leukemia.
    Otero L; Ornellas MH; Dobbin J; de Souza Fernandez T
    Int J Lab Hematol; 2008 Aug; 30(4):346-8. PubMed ID: 18665834
    [No Abstract]   [Full Text] [Related]  

  • 5. Not all imatinib resistance in CML are BCR-ABL kinase domain mutations.
    Wei Y; Hardling M; Olsson B; Hezaveh R; Ricksten A; Stockelberg D; Wadenvik H
    Ann Hematol; 2006 Dec; 85(12):841-7. PubMed ID: 17006667
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia.
    Soverini S; Colarossi S; Gnani A; Rosti G; Castagnetti F; Poerio A; Iacobucci I; Amabile M; Abruzzese E; Orlandi E; Radaelli F; Ciccone F; Tiribelli M; di Lorenzo R; Caracciolo C; Izzo B; Pane F; Saglio G; Baccarani M; Martinelli G;
    Clin Cancer Res; 2006 Dec; 12(24):7374-9. PubMed ID: 17189410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up.
    Lahaye T; Riehm B; Berger U; Paschka P; Müller MC; Kreil S; Merx K; Schwindel U; Schoch C; Hehlmann R; Hochhaus A
    Cancer; 2005 Apr; 103(8):1659-69. PubMed ID: 15747376
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imatinib does not substantially modify the glycemic profile in patients with chronic myeloid leukaemia.
    Mariani S; Tornaghi L; Sassone M; Basciani S; Buzzetti R; Gambacorti-Passerini C; Spera G; Gnessi L
    Leuk Res; 2010 Jan; 34(1):e5-7. PubMed ID: 19717189
    [No Abstract]   [Full Text] [Related]  

  • 9. Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML).
    Walz C; Sattler M
    Crit Rev Oncol Hematol; 2006 Feb; 57(2):145-64. PubMed ID: 16213151
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic response.
    Press RD; Galderisi C; Yang R; Rempfer C; Willis SG; Mauro MJ; Druker BJ; Deininger MW
    Clin Cancer Res; 2007 Oct; 13(20):6136-43. PubMed ID: 17947479
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Duplication of the Ph-chromosome as a possible mechanism of resistance to imatinib mesylate in patients with chronic myelogenous leukemia.
    Ossard-Receveur A; Bernheim A; Clausse B; Danglot G; Fauvet D; Leon B; Lozach F; Bories D; Brouzes C; Bourhis JH; Turhan AG
    Cancer Genet Cytogenet; 2005 Dec; 163(2):189-90. PubMed ID: 16337868
    [No Abstract]   [Full Text] [Related]  

  • 12. A mutation conferring resistance to imatinib at the time of diagnosis of chronic myelogenous leukemia.
    Roche-Lestienne C; Laï JL; Darré S; Facon T; Preudhomme C
    N Engl J Med; 2003 May; 348(22):2265-6. PubMed ID: 12773665
    [No Abstract]   [Full Text] [Related]  

  • 13. [Efficacy of imatinib mesylate, a specific inhibitor of BCR/ABL tyrosine kinase, on chronic myeloid leukemia in blast phase].
    Zhang GC; Zheng D; Li QH; Li XH; Cai CC; Luo SK; Li J; Peng AH; Tong XZ; Tan EX; Hong WD
    Ai Zheng; 2004 Dec; 23(12):1696-9. PubMed ID: 15601563
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Concomitant use of imatinib and warfarin in chronic phase chronic myeloid leukemia patients does not interfere with drug efficacy.
    Breccia M; Santopietro M; Loglisci G; Stagno F; Cannella L; Carmosino I; Alimena G
    Leuk Res; 2010 Aug; 34(8):e224-5. PubMed ID: 20356624
    [No Abstract]   [Full Text] [Related]  

  • 15. Specific assessment of BCR-ABL transcript overexpression and imatinib resistance in chronic myeloid leukemia patients.
    Bianchini M; De Brasi C; Gargallo P; Gonzalez M; Bengió R; Larripa I
    Eur J Haematol; 2009 Apr; 82(4):292-300. PubMed ID: 19191867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imatinib mesylate may improve fasting blood glucose in diabetic Ph+ chronic myelogenous leukemia patients responsive to treatment.
    Breccia M; Muscaritoli M; Aversa Z; Mandelli F; Alimena G
    J Clin Oncol; 2004 Nov; 22(22):4653-5. PubMed ID: 15542819
    [No Abstract]   [Full Text] [Related]  

  • 17. Understanding the molecular basis of imatinib mesylate therapy in chronic myelogenous leukemia and the related mechanisms of resistance. Commentary re: A. N. Mohamed et al., The effect of imatinib mesylate on patients with Philadelphia chromosome-positive chronic myeloid leukemia with secondary chromosomal aberrations. Clin. Cancer Res., 9: 1333-1337, 2003.
    Marcucci G; Perrotti D; Caligiuri MA
    Clin Cancer Res; 2003 Apr; 9(4):1248-52. PubMed ID: 12684391
    [No Abstract]   [Full Text] [Related]  

  • 18. BCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using strict sensitivity criteria.
    Branford S; Seymour JF; Grigg A; Arthur C; Rudzki Z; Lynch K; Hughes T
    Clin Cancer Res; 2007 Dec; 13(23):7080-5. PubMed ID: 18056186
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Attentive questions about treatment of chronic myelogenous leukemia with imatinib mesylate].
    Chen SS
    Zhonghua Xue Ye Xue Za Zhi; 2006 Jul; 27(7):433-5. PubMed ID: 17147242
    [No Abstract]   [Full Text] [Related]  

  • 20. Chronic myeloid leukemia with e19a2 atypical transcript: early imatinib resistance and complete response to dasatinib.
    Martin SE; Sausen M; Joseph A; Kingham BF
    Cancer Genet Cytogenet; 2010 Sep; 201(2):133-4. PubMed ID: 20682399
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.